Actively Recruiting
Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2025-05-23
200
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
S
Shanghai East Hospital of Tongji University
Collaborating Sponsor
AI-Summary
What this Trial Is About
We are using a tool called QtNGS (quantitative targeted amplicon-based next-generation sequencing ) to measure the abundance of local pathogens in patients with ventilator-associated lower respiratory tract infections. We hypothesize that changes in pathogen abundance before and after treatment are related to patient outcomes. This study aims to evaluate the effectiveness of the tool by analyzing the changes in pathogen abundance and exploring the relationship between these changes and clinical outcomes.
CONDITIONS
Official Title
Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years and above.
- Have been on mechanical ventilation (endotracheal intubation or tracheotomy) for more than 48 hours.
- Have a lower respiratory tract infection indicated by at least two of the following: abnormal body temperature (greater than 38.56C or less than 36.56C), abnormal white blood cell count (greater than 12x10^9/L or less than 4x10^9/L), or purulent tracheal secretions.
You will not qualify if you...
- Bronchoscopy and respiratory specimen collection were not performed at screening (Day 1) and after 3 days of treatment (Day 4).
- Patient or family refuses to participate in the study.
- After initial screening, bronchoscopy bacterial culture showed no infection by study-related pathogens.
- Infection must be confirmed by a single positive bacterial culture with pathogen quantification 10^4 cfu/ml or "++" and more.
- Patient must have a single infection with one of the following pathogens: Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, or Staphylococcus aureus.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
he First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 21000
Actively Recruiting
Research Team
W
Wenkui Sun, Dr
CONTACT
J
Ji Zhou, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here